mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
linifanib |
GDSC1000 |
pan-cancer |
AAC |
-0.03 |
0.4 |
mRNA |
selumetinib:GDC-0941 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.031 |
0.4 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.032 |
0.4 |
mRNA |
GNF-2 |
GDSC1000 |
pan-cancer |
AAC |
-0.044 |
0.4 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.4 |
mRNA |
Repligen 136 |
CTRPv2 |
pan-cancer |
AAC |
0.032 |
0.4 |
mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
0.027 |
0.4 |
mRNA |
ZSTK474 |
GDSC1000 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
Zibotentan |
GDSC1000 |
pan-cancer |
AAC |
-0.029 |
0.4 |